Posterior Cortical Atrophy (PCA) is a neurodegenerative syndrome characterized by progressive decline in visual processing, spatial orientation, and posterior cortical functions[1]. Also known as the Visual Variant of Alzheimer's Disease, PCA typically presents with prominent visuospatial and visuoperceptual deficits while memory remains relatively preserved early in the disease course[2]. Treatment approaches for PCA overlap substantially with Alzheimer's disease therapeutics, but must address the unique symptom profile of visual and spatial dysfunction[3].
Acetylcholinesterase inhibitors (AChEIs) are the cornerstone of symptomatic treatment for PCA, given its strong association with Alzheimer's disease pathology[4]:
AChEIs work by inhibiting acetylcholinesterase, increasing synaptic acetylcholine levels in cortical and hippocampal regions affected in AD and PCA[8]. Clinical experience suggests moderate efficacy in PCA, though randomized controlled trials specific to PCA are limited[9].
NMDA receptor antagonist therapy with memantine (Namenda) 10 mg twice daily may provide neuroprotective benefits and modulate glutamate excitotoxicity[10]. Evidence for memantine efficacy in PCA specifically is anecdotal, but rationales include:
Given the amyloid-beta pathology underlying most PCA cases, disease-modifying therapies targeting amyloid are theoretically applicable[17]:
Tau pathology is prominent in PCA, driving cortical degeneration[21]:
Occupational therapy is essential for maintaining independence and quality of life in PCA[29]:
Regular physical exercise provides both cognitive and physical benefits[33]:
For patients with associated language or reading difficulties[37]:
Mesenchymal stem cell (MSC) transplantation under investigation for neuroprotection and immunomodulation[42].
PCA patients should be considered for clinical trials given the limited treatment options[53]:
PCA typically progresses over 8-12 years, with treatment goals including[57]:
Benson et al. Posterior cortical atrophy: variant of Alzheimer's disease? Neurology. Neurology. 1988. ↩︎
Mendez et al. Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease. Dement Geriatr Cogn Disord Extra. 2012. ↩︎
Crutch et al. Posterior Cortical Atrophy. Lancet Neurol. 2012. ↩︎
Rogalski et al. Likelihood of clinical response to acetylcholinesterase inhibitors in posterior cortical atrophy. Dement Geriatr Cogn Disord. 2011. ↩︎
Johnson et al. Donepezil for visual dysfunction in posterior cortical atrophy. J Neurol Neurosurg Psychiatry. 2010. ↩︎
Birks et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015. ↩︎
Olin et al. Galantamine for AD: a meta-analysis of clinical efficacy. J Clin Psychopharmacol. 2002. ↩︎
Cummings et al. Cholinergic therapy for neurodegenerative diseases. J Neurochem. 2012. ↩︎
Schott et al. Using CSF acetylcholinesterase to response to cholinesterase inhibitors in PCA. Neurology. 2006. ↩︎
Olney et al. Memantine: a NMDA receptor antagonist for Alzheimer's disease. Expert Opin Pharmacother. 2007. ↩︎
Tariot et al. Memantine treatment in patients with moderate to severe Alzheimer disease. JAMA. 2004. ↩︎
Peli et al. Prism therapy for hemianopia. Optom Vis Sci. 1991. ↩︎
Warren et al. Low vision rehabilitation. Invest Ophthalmol Vis Sci. 2013. ↩︎
Lyketsos et al. Neuropsychiatric symptoms in Alzheimer's disease. Lancet Neurol. 2011. ↩︎
Salzman et al. Atypical antipsychotics in AD. Am J Psychiatry. 2008. ↩︎
Wu et al. Melatonin for sleep disorders in neurodegenerative disease. J Pineal Res. 2007. ↩︎
Bateman et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012. ↩︎
van Dyck et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023. ↩︎
Cummings et al. Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement. 2023. ↩︎
Nicoll et al. A beta antibodies in AD: implications for treatment. Nat Rev Neurol. 2023. ↩︎
Ahmed et al. Tau pathology in posterior cortical atrophy. Acta Neuropathol. 2015. ↩︎
Malia et al. Anti-tau therapies in development. Nat Med. 2023. ↩︎
Wischik et al. Tau aggregation inhibitor therapy in AD. J Prev Alzheimers Dis. 2015. ↩︎
Long et al. BDNF in neurodegenerative disease. Neurobiol Dis. 2012. ↩︎
Galasko et al. Antioxidants in AD. Arch Neurol. 2007. ↩︎
Zanieri et al. Cognitive rehabilitation in posterior cortical atrophy. Neurol Sci. 2013. ↩︎
Kaski et al. Compensation strategies in posterior cortical atrophy. Cortex. 2016. ↩︎
Clare et al. Cognitive rehabilitation for dementia. Cochrane Database Syst Rev. 2019. ↩︎
Gitlin et al. Occupational therapy in dementia care. Clin Interv Aging. 2007. ↩︎
Stark et al. Home modifications for visually impaired elders. J Am Geriatr Soc. 2010. ↩︎
Mann et al. Assistive technology for visually impaired in dementia. Gerontechnology. 2013. ↩︎
Dooley et al. Functional independence in posterior cortical atrophy. Dement Geriatr Cogn Disord. 2015. ↩︎
Colcombe et al. Fitness effects on brain. J Gerontol B Psychol Sci Soc Sci. 2006. ↩︎
Baker et al. Exercise improves cognition in MCI. Arch Neurol. 2010. ↩︎
Muir-Hunter et al. Balance and falls in cognitive impairment. Clin Interv Aging. 2014. ↩︎
Liu et al. Strength training in older adults. J Gerontol A Biol Sci Med Sci. 2011. ↩︎
Machado et al. Language therapy in posterior cortical atrophy. Dement Neuropsychol. 2019. ↩︎
Price et al. Reading strategies in posterior cortical atrophy. Cogn Neuropsychol. 2012. ↩︎
Fried-Oken et al. AAC for neurodegenerative disease. J Speech Lang Hear Res. 2012. ↩︎
Nagahara et al. AAV-BDNF gene therapy for neurodegenerative disease. Mol Ther. 2010. ↩︎
Huentelman et al. Gene therapy for monogenic neurodegenerative disease. Mol Ther. 2022. ↩︎
Kim et al. Stem cell therapy for neurodegenerative disease. Stem Cells Transl Med. 2023. ↩︎
Hampel et al. Precision medicine in AD. Mol Psychiatry. 2023. ↩︎
Blennow et al. Biomarkers for AD. Lancet Neurol. 2023. ↩︎
Nordin et al. Visuospatial contribution to postural control in PCA. Gait Posture. 2010. ↩︎
Shumway-Cook et al. Fall prevention in community elders. Phys Ther. 2000. ↩︎
Clemson et al. Home fall prevention. J Am Geriatr Soc. 2008. ↩︎
Carnaby et al. Dysphagia in neurodegenerative disease. Dysphagia. 2012. ↩︎
Logemann et al. Diet modification in dysphagia. Head Neck. 2008. ↩︎
Callahan et al. PEG tubes in advanced dementia. J Am Geriatr Soc. 2000. ↩︎
Fletcher et al. Low vision rehabilitation in dementia. Optom Vis Sci. 2014. ↩︎
Warren et al. Orientation and mobility training. J Vis Impair Blind. 2013. ↩︎
Schott et al. Clinical trials in posterior cortical atrophy. Lancet Neurol. 2015. ↩︎
Ryman et al. Clinical trials in atypical Alzheimer variants. Neurology. 2020. ↩︎
Valenti et al. Outcome measures in PCA clinical trials. Alzheimers Res Ther. 2019. ↩︎
Ossenkoppele et al. Biomarker confirmation in PCA. JAMA Neurol. 2015. ↩︎
Lehmann et al. Prognosis in posterior cortical atrophy. Neurology. 2012. ↩︎
Graff et al. Maintenance of function in dementia. J Neurol Neurosurg Psychiatry. 2008. ↩︎
Spector et al. Cognitive stimulation therapy for dementia. Br J Psychiatry. 2003. ↩︎
Lyketsos et al. Managing behavioral symptoms in dementia. JAMA. 2006. ↩︎
Brodaty et al. Caregiver interventions in dementia. Med J Aust. 2003. ↩︎
Sepic et al. Advance care planning in neurodegenerative disease. Neurology. 2018. ↩︎